Dataset Information

Febrile Infant Diagnostic Assessment and Outcome Olink Dataset

ABSTRACT: The FIDO (Febrile Infant Diagnostic assessment and Outcome) study aimed to look at different diagnostic approaches to identify infants with a fever at low and high-risk of serious infection. FIDO was a multicentre prospective observational cohort study that enrolled infants ≤90 days of age presenting with fever to 35 Paediatric Emergency Research in the UK and Ireland (PERUKI) sites. The FIDO study was prospectively registered at ClinicalTrials.gov (NCT05259683; 28 February 2022). Where possible, residual plasma volume was collected and stored from infants for proteomic and biomarker analysis.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

DISEASE(S): Bacterial Sepsis

SUBMITTER: Clare Mills

LAB HEAD: Clare Mills

PROVIDER: PAD000035 | Pride | 2026-05-29

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	FIDO_Metadata_PRIDE.csv	Csv
	FIDO_Olink.npx.csv	Csv
	checksum.txt	Txt

Items per page:

1 - 3 of 3

Publications

Applying clinical decision aids for the assessment and management of febrile infants presenting to emergency care in the UK and Ireland: Febrile Infant Diagnostic Assessment and Outcome (FIDO) Study protocol.

Umana Etimbuk E Mills Clare C Norman-Bruce Hannah H Wilson Kathryn K Mitchell Hannah H McFetridge Lisa L Woolfall Kerry K Lynn Fiona A FA McKeeman Gareth G Foster Steven S Barrett Michael M Roland Damian D Lyttle Mark D MD Watson Chris C Waterfield Thomas T

BMJ open 20230920 9

<h4>Introduction</h4>Febrile infants 90 days and younger are at risk of invasive bacterial infections (bacteraemia and meningitis) and urinary tract infections. Together this is previously termed serious bacterial infection with an incidence of approximately 10-20%. The National Institute for Health and Care Excellence guidance advocates a cautious approach with most infants requiring septic screening, parenteral broad-spectrum antibiotics and hospital admission. Internationally, variations exis ...[more]

PMID: 37730397

Similar Datasets

Project description:Background and Objectives: Brain age is a global measure that compares structural brain MRI with large reference datasets. Predicted age deviation (PAD) is the deviation between predicted brain age and chronological age, with positive values indicating advanced aging. Identifying blood-based biomarkers that approximate brain PAD could provide an accessible and cost-effective measure of brain health as an alternative to MRI, but no blood-based biomarkers have yet been identified. This study aimed to investigate novel blood-based biomarkers associated with accelerated PAD using an unbiased proteomics approach to discover new biomarkers. Methods: This study is a secondary analysis with a cross-sectional case-control design using the LIMBIC-CENC dataset as a discovery approach to understand novel biomarker patterns. Brain age was estimated using brainageR in 137 participants aged ≤40 years with no substantial cognitive deficits or neurological disorders. Cases (n=76) included individuals with brain age ≥5 years older than chronological age, whereas controls (n=61) had brain age equal to or younger than chronological age (PAD range: -1.3 to 0; mean=-0.9) and were otherwise matched on demographics and clinical features. Unbiased proteomic profiling of ~5,400 proteins was performed using the Olink Explore platform. Differential protein expression between groups was assessed using Wilcoxon tests with Benjamini-Hochberg correction. Receiver operating characteristic (ROC) analysis was performed on probabilities derived from generalized linear models (GLMs) to identify optimal protein combinations, prioritizing maximizing both sensitivity and negative predictive value. Results: Olink analyses identified 418 proteins that were significantly different between groups after multiple-comparison correction. Up-regulated proteins in participants with PAD≥5 years included: component inhibitor-nuclear factor kappa-b kinase (CHUK), methenyltetrahydrofolate synthetase domain containing (MTHFSD), and epidermal growth factor (EGF), with log2 fold changes of 1.70-1.80. Insulin-like peptide 3 (INSL3) was the most downregulated protein (log2 fold change -2.27). Enriched pathways involved nuclear factor kappa-b (NF-κB), heat-shock protein, and Wingless/Integrated (Wnt) signaling. Models including 6-7 dysregulated proteins (e.g., CHUK and INSL3) achieved AUCs>0.9, with sensitivities >0.90 and specificities >0.70. Discussion: These discovery-based findings warrant validation in larger cohorts and suggest potential for blood-based protein panel detection of early, clinically silent, pre-pathological accelerated brain aging changes when interventions may be most effective.